Health-economic analysis: Cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - Modelling outcomes in active luminal and fistulizing disease in adults

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 1, 2008, Pages 76-87

  Lindsay, J ^a   Punekar, Y S ^b   Morris, J ^b   Chung Faye, G ^c  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB;

ANUS FISTULA; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DISEASE COURSE; DRUG COST; ENTEROCUTANEOUS FISTULA; HEALTH CARE COST; HOSPITAL COST; HUMAN; MAINTENANCE THERAPY; MODEL; MORTALITY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROBABILITY; RECURRENT DISEASE; REMISSION; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BODY WEIGHT; COST-BENEFIT ANALYSIS; CROHN DISEASE; DRUG COSTS; FEMALE; GASTROINTESTINAL AGENTS; HOSPITALIZATION; HUMANS; INTESTINAL FISTULA; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 44649154404     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03709.x     Document Type: Article

References (52)

1. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002 8 : 244 50.
2. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993 105 : 1716 23.
3. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005 54 : 237 41.
4. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995 30 : 699 706.
5. Hanauer SB, Cohen RD, Becker RV, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther 1998 20 : 1009 28.
6. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004 53 : 1471 8.
7. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997 32 : 1134 9.
8. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000 342 : 1627 32.
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 9.
10. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 132 : 52 65.
11. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007 357 : 239 50.
12. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004 53 (Suppl 5. V1 16.
13. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976 70 : 439 44.
14. Harvey R, Bradshaw J. A simple index for Crohn's disease activity. Lancet 1980 1 : 514.
15. National Institute of Health and Clinical Excellence (NICE). Guidance on the Use of Infliximab for Crohn's Disease. London : Technology Appraisal Guidance 40, April 2002.
16. Travis S, Trange E, Lemann A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006 55 (Suppl. 1 i16 35.
17. Rutgeerts P, Diamond R, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006 63 : 433 42.
18. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004 126 : 402 13.
19. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 350 : 876 85.
20. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003 98 : 2232 8.
21. Lichtenstein G, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn's disease. Gastroenterology 2005 128 : 862 9.
22. Lichtenstein G, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalisations and surgery. Am J Gastroneterol 2004 99 : 91 6.
23. Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005 17 : 1047 52.
24. Jess T, Loftus E, Scott Harmsen W, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut 2006 55 : 1248 54.
25. Lichtenstein G, Feagan B, Cohen R, et al. Serious infections and mortality in association with therapies for Crohn's Disease: TREAT registry. Clin Gastroenterol Hepatol 2006 4 : 621 30.
26. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337 : 1029 35.
27. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999 340 : 1398 405.
28. Marchal L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004 19 : 749 54.
29. Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006 55 : 1124 30.
30. National Institute of Health and Clinical Excellence (NICE). Guidance on the Use of Infliximab for Psoriasis. London : Technology Appraisal Guidance 134, January 2008.
31. Department of Health. NHS Reference Costs 2005-06. Published 7 December 2006. Available at http://www.dh.gov.uk/en/publicationsandstatistics/ publications/PublicationsPolicyAndGuidance/DH_062884.
32. Schering-Plough Ltd. UK Advisory Panel on Resource Use for CD Patients in Individual Post-Surgery Health States. Data on File. Available on request : Schering-Plough Ltd, 2007.
33. Casellas F, Arenas J, Baudet J. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005 11 : 488 96.
34. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 35 : 1095 108.
35. NICE. Guide to the Methods of Technology Appraisal. National Institute of Health and Clinical Excellence, April 2004 : 26.
36. Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007 26 : 1509 20.
37. Jaisson-Hot I, Flourié B, Descos L, Colin C. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004 20 : 274 9.
38. Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease. Health Technol Assess 2003 7 : 1 67.
39. Arseneau KO, Cohn SM, Cominelli F, Connors AF. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology 2001 120 : 1640 56.
40. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999 117 : 49 57.
41. Casellas F, Rodrigo L, Niño P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis 2007 13 : 1395 400.
42. Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohn's disease treatment with infliximab. Dig Dis Sci 2008 53 : 1033 41.
43. Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol 2007 13 : 5238 44.
44. Gregor JC, McDonald JWD, Klar N, et al. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997 3 : 265 76.
45. Saro C, da la Coba C, Casado MA, et al. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther 2007 10 : 1313 23.
46. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002 35 : 151 6.
47. Woehl A, Hawthorne B, Morgan C, Punekar Y, McEwan P. The epidemiology and healthcare resource use in patients with Crohn's disease: a population based UK study. Value Health 2007 10 : A355.
48. Somerville M, Brooksby A, Scott DG. Maximizing the use of scarce resources: vial optimization. Rheumatology (Oxford) 2006 45 : 353 4.
49. Towse A. What is NICE's threshold? An external view. In : Devlin N, Towse A, eds. Cost Effectiveness Threshold: Economic and Ethical Issues. London : King's Fund/Office of Health Economics, 2002.
50. D'Haens G, Baert F, Assche GV, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008 371 : 660 7.
51. Sandborn W, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007 146 : 829 38.
52. Makowiec F, Jehle EC, Starlinger M. Clinical course of perianal fistulas in Crohn's disease. Gut 1995 37 : 696 701.